Browse > Article

MicroRNA Expression Profiling in Cell and Mouse Models of Fabry Disease to Identify Biomarkers for Fabry Disease Nephropathy  

Jung, Namhee (Department of Biochemistry, School of Medicine, Ewha Womans University)
Park, Saeyoung (Department of Biochemistry, School of Medicine, Ewha Womans University)
Jeon, Yeo Jin (Department of Biochemistry, School of Medicine, Ewha Womans University)
Choi, Yoonyoung (Department of Biochemistry, School of Medicine, Ewha Womans University)
Jung, Sung-Chul (Department of Biochemistry, School of Medicine, Ewha Womans University)
Publication Information
Journal of The Korean Society of Inherited Metabolic disease / v.15, no.3, 2015 , pp. 127-137 More about this Journal
Abstract
Purpose: The main aim of this study was to compare and analyze expression profiles of microRNAs (miRNAs) to establish miRNA signature of Fabry nephropathy related epithelial mesenchymal transition (EMT). Methods: Expression profiles of miRNAs in kidney tissue samples and cell lines from normal and Fabry disease mouse model were examined by miRNA expression microarray analysis followed by quantitative real-time polymerase chain reaction analysis (qRT-PCR). Results: In the miRNA expression microarray analysis of Fabry mouse kidney tissues compared to wild type mouse, 5 and 3 miRNAs among 1,247 miRNAs examined were up- and down-regulated, respectively. Among them, miR-149-5p was down-regulated about 2-fold in Fabry kidney samples. The down-regulations of miR-149-5p were observed in kidney tissues of under 35 week-old-Fabry mice. However, this down-regulation was not observed in kidney tissues of 42 week-old Fabry mice. In SV40 MES 13 cells, mouse mesangial cells, treated with globotriaosylsphingosine (lyso-Gb3), miR-149-5p was also downregulated. The down-regulation of miR-149-5p induced up-regulation of its target genes related to EMT. Conclusion: The miRNA expression array and qRT-PCR results show that miR-149-5p expression was decreased in kidney tissues of Fabry mice compared to wild type mice under 35 weeks of age. Along with the observation of miR-149-5p expression in Fabry disease cell models, these results indicate that the down-regulated miR-149-5p were related to the biological response of mesangial cells to lyso-Gb3 and also have influence to the transcriptional up-regulation of its target genes. These results suggest miR-149-5p might play important roles in the Fabry nephropathy.
Keywords
Fabry disease; MicroRNAs; Biomarkers;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Xu K, Liu X, Mao X, Xue L, Wang R, Chen L, et al. MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem 2015;35:499-515.   DOI
2 Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer 2013;108:644-52.   DOI
3 Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 2013;91:431-7.   DOI
4 Rak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol 2013;4:21.
5 Rana S, Malinowska K, Zoller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013;15:281-95.   DOI
6 Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG, Sun BM. MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. Int J Immunopathol Pharmacol 2012;25:871-81.   DOI
7 Zhang Y, Guo X, Xiong L, Yu L, Li Z, Guo Q, et al. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway. Mol Cancer 2014;13:253.   DOI
8 Chan SH, Huang WC, Chang JW, Chang KJ, Kuo WH, Wang MY, et al. MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis. Oncogene 2014;33:4496-507.   DOI
9 Li P, Shan JX, Chen XH, Zhang D, Su LP, Huang XY, et al. Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. Cell Res 2015;25:588-603.   DOI
10 Shin YJ, Jeon YJ, Jung N, Park JW, Park HY, Jung SC. Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease. Mol Med Rep 2015;12:5049-57.   DOI
11 Ke Y, Zhao W, Xiong J, Cao R. miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1. Biochem Res Int. 2013;2013:506731.
12 Zuo JH, Zhu W, Li MY, Li XH, Yi H, Zeng GQ, et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem 2011;112: 2508-17.   DOI
13 Shiozuka C, Taguchi A, Matsuda J, Noguchi Y, Kunieda T, Uchio-Yamada K, et al. Increased globotriaosylceramide levels in a transgenic mouse expressing human a1,4-galactosyltransferase and a mouse model for treating Fabry disease. J Biochem 2011;149:161-70.   DOI
14 Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002;62:1933-46.   DOI
15 Germain DP. Fabry disease. Orphanet J Rare Dis 2010;5:30.   DOI
16 Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 2009;119:2561-7.   DOI
17 Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE, O'Callaghan M. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies. J Invest Dermatol 2004;122:900-8.   DOI
18 Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008;105:2812-7.   DOI
19 Wijburg FA, Benichou B, Bichet DG, Clarke LA, Dostalova G, Fainboim A, et al. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. PLoS One 2015;10:e0124987.   DOI
20 Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010;25:2168-77.   DOI
21 Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med 2015;21:998-1009.   DOI
22 Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003;64: 801-7.   DOI
23 Wang JY, Gao YB, Zhang N, Zou DW, Wang P, Zhu ZY, et al. miR-21 overexpression enhances TGFbeta1- induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol 2014;392: 163-72.   DOI
24 Jeon YJ, Jung N, Park JW, Park HY, Jung SC. Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide. PLoS One 2015;10:e0136442.   DOI
25 Morizane R, Fujii S, Monkawa T, Hiratsuka K, Yamaguchi S, Homma K, et al. miR-34c attenuates epithelial-mesenchymal transition and kidney fibrosis with ureteral obstruction. Sci Rep 2014;4:4578.
26 Liu T, Nie F, Yang X, Wang X, Yuan Y, Lv Z, et al. MicroRNA-590 is an EMT-suppressive microRNA involved in the TGFbeta signaling pathway. Mol Med Rep 2015;12:7403-11.   DOI
27 Morizane R, Fujii S, Monkawa T, Hiratsuka K, Yamaguchi S, Homma K, et al. miR-363 induces transdifferentiation of human kidney tubular cells to mesenchymal phenotype. Clin Exp Nephrol 2015.
28 Xiao L, Zhou X, Liu F, Hu C, Zhu X, Luo Y, et al. MicroRNA-129-5p modulates epithelial-to-mesenchymal transition by targeting SIP1 and SOX4 during peritoneal dialysis. Lab Invest 2015;95:817-32.   DOI
29 Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev 2015;87:3-14.   DOI
30 Huang Y, Tong J, He F, Yu X, Fan L, Hu J, et al. miR-141 regulates TGF-beta1-induced epithelialmesenchymal transition through repression of HIPK2 expression in renal tubular epithelial cells. Int J Mol Med 2015;35:311-8.   DOI
31 Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis 2015;35:3-11.   DOI
32 Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010;116:117-25.   DOI
33 Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011;22:1686-98.   DOI
34 Oba S, Mizutani T, Suzuki E, Nishimatsu H, Takahashi M, Ogawa Y, et al. A useful method of identifying of miRNAs which can down-regulate Zeb-2. BMC Res Notes 2013;6:470.   DOI
35 Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer 2013;132:745-54.   DOI
36 Zhang L, Sun J, Wang B, Ren JC, Su W, Zhang T. MicroRNA-10b Triggers the Epithelial-Mesenchymal Transition (EMT) of Laryngeal Carcinoma Hep-2 Cells by Directly Targeting the E-cadherin. Appl Biochem Biotechnol 2015;176:33-44.   DOI
37 Palmieri D, Capponi S, Geroldi A, Mura M, Mandich P, Palombo D. TNFalpha induces the expression of genes associated with endothelial dysfunction through p38MAPK-mediated down-regulation of miR-149. Biochem Biophys Res Commun 2014;443:246-51.   DOI